HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y. Articles by Mangelsdorf, D. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y. Articles by Mangelsdorf, D. J.

LuXuRies of Lipid Homeostasis: The Unity of Nuclear Hormone Receptors, Transcription Regulation, and Cholesterol Sensing

Department of Pharmacology Howard Hughes Medical Institute University of Texas Southwestern Medical Center 5323 Harry Hines Blvd. Dallas Tx 75390-9050

Correspondence: DJM. E-mail davo.mango{at}utsouthwestern.edu; fax 214-648-5419.

	ABSTRACT

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
Cholesterol homeostasis is maintained by a regulatory network that controls both the acquisition and elimination of cholesterol. Recent studies have elucidated a mechanism by which cholesterol metabolism is transcriptionally regulated by several classes of orphan nuclear receptors. In particular, the liver X receptors, LXR and LXRß, appear to serve as key sensors of intracellular sterol levels by regulating the expression of genes that control cholesterol absorption, storage, transport, and elimination. LXRs are also involved in fatty acid metabolism by their ability to increase the expression of sterol regulatory element–binding protein 1c (SREBP-1c). These findings define LXRs as potential therapeutic targets for the treatment of lipid disorders.

	INTRODUCTION

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
Liver X receptors (LXRs) and ß are members of the superfamily of nuclear hormone receptor proteins (1). They are so named because a human LXR that was first identified by screening a liver cDNA library is highly expressed in liver (2,3). Like other nuclear hormone receptor proteins, LXRs are composed of a highly conserved zinc-finger DNA-binding domain and a less conserved ligand-binding domain. LXR (NR1H3, also called RLD-1) and LXRß (NR1H2, also called UR, NER1, OR-1, and RIP15) are highly related and share ~77% amino acid sequence identity in both their DNA- and ligand-binding domains (4). LXR-encoding mRNA is highly abundant in liver and other tissues involved in lipid metabolism, whereas LXRß-encoding mRNA is present in all tissues examined (Figure1).

Both LXR and LXRß form obligate heterodimers with the retinoid X receptor (RXR) to result in ligand-activated transcription factors that can be activated by ligands (i.e., lipids) for either RXR or LXR (5). RXR–LXR heterodimers bind to a specific DNA sequence called the LXR response element (LXRE), which consists of two hexanucleotide sequences separated by four bases (Figure 1) (6).

View larger version (68K): [in this window] [in a new window]   Figure 1. Characterization of oxysterol receptors LXR and LXRß. A. Tissue distribution of LXR and LXRß. Shown is a gel blot analysis of adult male mouse tissue mRNA (5µg) probed with DNA fragments that encode sequences of LXR, LXRß, or cyclophilin as control. B. The consensus DNA sequence that defines the LXR response element (LXRE) to which functional LXRs bind to promote transcription. The LXRE consists of a direct repeat of the indicated hexanucleotide sequence separated by four bases.

To study the biological function of LXRs, mouse models lacking LXR, LXRß, or both LXRs have been generated by targeted gene disruption (14, 15; J. Lobacarro and D. Mangelsdorf, unpublished data). These mouse models have revealed the key role of LXRs in regulating the expression of genes involved in cholesterol catabolism, absorption, and transport, as well as fatty acid synthesis (Table 1). The purpose of this review is to discuss recent and ongoing studies into the regulatory role of LXRs in various aspects of lipid homeostasis.

	CHOLESTEROL HOMEOSTASIS

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

LXR upregulates the transcription of Cyp7a1 by directly binding to an LXRE in the promoter of this gene (8,14). Furthermore, the liver-specific expression of CYP7A1 requires LRH-1 (i.e., liver receptor homolog-1; also called CPF and FTF), a monomeric orphan nuclear receptor (5). The transcription of Cyp7a1 is also regulated via feedback inhibition. Specifically, the bile acid receptor FXR (i.e., farnesoid X receptor) (18,19) binds bile acids and induces the expression of SHP (i.e., small heterodimer partner), an orphan nuclear receptor that preferentially dimerizes with LRH-1 and represses a number of enterohepatic genes involved in synthesis and transport of bile acids, including Cyp7a1. In this way, LXR and FXR act as the yin and yang of bile acid metabolism, operating together to tightly regulate bile acid homeostasis, respectively functioning, with a cholesterol precursor and cholesterol metabolite, to up- and downregulate Cyp7a1 (Figure 2). Induction of the Cyp7a1 by dietary cholesterol occurs in both the mouse and rat, but not in the human or hamster (4), which suggests that disparate regulatory pathways may exist among species.

View larger version (20K): [in this window] [in a new window]   Figure 2. LXR and FXR as the regulatory yin and yang of intracellular cholesterol turnover. The RXR–LXR dimer becomes a functional transcription factor when either protomeric constituent binds ligand; the blue circle associated with the LXR in the schematic represents 24(S),25-epoxycholesterol. The dimer therefore binds to its cognate nucleotide sequence (i.e., the LXRE) in the promoter of Cyp7a1, a gene crucial to cholesterol catabolism. Activation of the LXRE by the dimer is enabled through an interaction with LRH-1. As cholesterol is shuttled into bile acid (represented by white circle) production, FXR becomes functional as a transcription factor in the expression of the SHP-encoding gene. SHP binds to LRH-1 and limits the effectiveness of the RXR–LXR dimer. For a list of genes that are activated by LXR, see Table 1.

CHOLESTEROL ABSORPTION
Dietary and secreted biliary cholesterol enters the intestinal lumen and is absorbed by proximal enterocytes. In the mouse, LXR and RXR agonists, which are metabolic indicators of active cholesterol turnover, decrease cholesterol absorption (12). This net reduction in cholesterol uptake is associated with an RXR/LXR-mediated upregulation of LXRE-containing genes (20–22) that encode ATP-binding cassette (ABC) transporters. ABC transporters are transmembrane proteins that utilize the energy of ATP hydrolysis to move substrates across cell membranes (23).

In the small intestine, at least three ABC transporters are transcriptionally regulated by LXRs (12,24) and putatively limit cholesterol absorption by pumping cholesterol back into the lumen of the gut. ABCA1 is a full transporter protein containing two symmetric halves, each composed of a six-transmembrane domain and an ATP-binding cassette. Mutations in the ABCA1 gene result in Tangier disease, which is characterized by a low concentration of plasma high-density lipoprotein (HDL) and the accumulation of cholesterol esters in tonsils, liver, spleen, intestinal mucosa, and macrophage foam cells (25–27). ABCA1 is upregulated by LXRs in both intestine and macrophages (12). In macrophages, ABCA1 facilitates reverse cholesterol transport (discussed below).

ABCG5 and ABCG8 are half-transporters, each composed of a single transmembrane domain and ATP-binding cassette (24), and are co-expressed exclusively in the liver and intestine. Mutations in either gene cause a rare autosomal recessive disorder called sitosterolemia, which is characterized by increased absorption of cholesterol and toxic plant sterols, and decreased biliary sterol secretion. In vivo and in vitro experiments indicate that ABCG5 and ABCG8 are direct targets of LXRs (24, 59). These findings strongly support the hypothesis that LXRs promote cholesterol loss by increasing biliary cholesterol secretion and limiting cholesterol absorption.

REVERSE CHOLESTEROL TRANSPORT
The elimination of cholesterol through bile acid production occurs exclusively in the liver, so that excess cholesterol from most other tissues must be returned to the liver, in a process termed "reverse cholesterol transport," for catabolic elimination. This process is especially important in macrophages, because excess cholesterol in these cells can lead to their conversion into foam cells, thereby promoting atherogenesis. Two ABC transporters, ABCA1 and ABCG1, are upregulated by LXR and RXR agonists in macrophages (12,28,29). As discussed above, ABCA1 is upregulated by LXRs to result in cholesterol efflux. ABCG1, a half-transporter protein, has also been implicated in the cellular efflux of cholesterol and phospholipid (30). ABCG1, identified by a subtractive hybridization technique as a gene induced during macrophage foam cell formation (29), is also an LXR target gene (28,29), and contains two functional LXREs (31). A novel ABC half-transporter, ABCG4, has also been characterized (20,32,33); it shares high sequence identity with ABCG1. Although still controversial, expression of ABCG4 is believed to be upregulated in response to oxysterols and retinoids in human macrophages, suggesting a possible role for this transporter in macrophage lipid homeostasis (33). To date, five members of the ABC transporter superfamily have thus been implicated as downstream mediators of LXR action and play important roles in cholesterol homeostasis.

In addition to dependence upon ABCA1 to make cellular cholesterol available to HDL particles, the primary serum transporters of cholesterol back to the liver, reverse cholesterol transport also relies on LXRs to induce the transcription of apolipoprotein E (apoE), a component of some nascent HDL particles (34). Free cholesterol is thereby esterified within HDL particles and either transported back to the liver for further catabolism and excretion, or transferred to other lipoproteins. In humans, this latter process is mediated by cholesterol ester transfer protein (CETP) (35). Not surprisingly, the gene for CETP has also been reported as a direct target of LXR (36).

LXRs have also been shown to govern the expression of lipoprotein lipase (LPL) (37). LXR facilitates the expression of LPL selectively in liver and macrophages, but not in other tissues that express LPL, so that a previously unsuspected role for LPL is implicated in reverse cholesterol transport. LPL was first characterized as the rate-limiting enzyme in triglyceride hydrolysis in circulating large lipoprotein particles (38). Depending on the system studied, LPL has been reported to have both pro-atherogenic and anti-atherogenic effects. One reason why LXR may upregulate LPL in macrophages would be in order to help clear serum of cholesterol-rich lipoproteins by remodeling triglyceride-rich chylomicrons and very low–density lipoproteins into chylomicron remnants and low-density lipoprotein for uptake by macrophages. In the macrophage, cholesterol esters could then be converted into oxysterols and free cholesterol for efflux and transport back to the liver by HDL. LPL can facilitate HDL-cholesterol uptake into liver cells by a mechanism that does not require the catalytic activity of the lipase (39). LPL expression also promotes maturation of HDL in mice (40).

Throughout the mechanisms of reverse cholesterol transport presented above, LXRs are implicated as key sensors of sterol metabolism, maintaining normal cholesterol balance by promoting sterol efflux from peripheral cells, increasing circulating HDL-cholesterol, and ultimately increasing hepatic sterol catabolism and excretion. LXR regulation of reverse cholesterol transport also suggests a role for LXRs in protecting against atherogenesis, a hypothesis that has been confirmed by studies of Apoe -/- mice in which activation of LXR reduced atherosclerosis (41).

	FATTY ACID SYNTHESIS

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
Depletion of LXRs not only disrupts the metabolism of cholesterol, but also affects fatty acid synthesis (14). The expression of several genes encoding crucial enzymes of this important lipid metabolic pathway is altered in Lxr null mice. Moreover, a role for LXRs in fatty acid metabolism is compellingly indicated from the finding that sterol regulatory element-binding protein-1c (SREBP-1c) is a direct target of LXR action (42–44). SREBP-1c is a transcription factor that governs the expression of enzymes involved in fatty acid synthesis (45–47). In Lxr knockout mice, the basal expression level of SREBP-1c is reduced substantially and does not respond to LXR agonists; as a consequence, the transcription of a number of fatty acid synthesizing enzymes fails to be upregulated in response to LXR-specific agonists (14,42–44). These enzymes include fatty acid synthase (FAS), the central enzyme in de novo lipogenesis, catalyzing all the steps in the conversion of malonyl-CoA to palmitate. A second enzyme that depends on LXR activation via SREBP-1c is stearoyl-CoA desaturase-1 (SCD-1), which catalyzes the 9-cis desaturation of stearoyl-CoA and palmitoyl-CoA to oleoyl-CoA and palmitoleoyl-CoA, respectively. Although the upregulation of both enzymes is considered an indirect effect of LXRs, presumably by increasing the transcription and cleavage of SREBP-1c (43), future studies are needed to address whether these and other genes are also directly regulated by LXRs.

Why do the LXRs, which act in many contexts to limit cellular cholesterol content, function to activate the SREBP-1c regulatory network of lipogenesis? One reason may be to coordinate levels of fatty acids and phospholipids, components that are essential to the mobilization of free cholesterol. For example, oleoyl-CoA, a product of SCD-1 catalysis, is the preferred substrate for cholesterol esterification. Therefore, by increasing SCD-1 activity via SREBP-1c, the LXRs would ultimately promote the esterification and storage of free cholesterol within the cell and protect the organism from toxic cholesterol accumulation. In addition, phospholipids facilitate bile acid flow, lipoprotein transport of excess cholesterol, and help maintain the appropriate ratio of cholesterol to other lipids in plasma membranes (42,44). Thus, the finding that LXRs function to promote lipogenesis provides a conceptual link between sterol and fatty acid metabolic pathways. Unfortunately, pharmacological activation of the LXR/RXR heterodimer can increase lipogenesis to potentially harmful levels, causing hypertriglyceridemia (43). If LXRs are to be considered as therapeutic targets within the context of cholesterol metabolism, their role in triglyceride metabolism must be addressed. The development of novel, gene- and tissue-selective LXR agonists, in a fashion similar to that accomplished in the development of selective estrogen receptor modulators (SERMs), may hold a key to the pharmacological control of cholesterol levels.

	HUMAN LXR AUTOREGULATION

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
Many nuclear receptors autoregulate their own expression. A classic example of this type of regulation is exhibited by the retinoic acid receptor RARß. The RARß2 gene promoter contains an RAR response element that is strongly responsive to retinoic acid (48–50). Recently, an autoregulatory function has been ascribed to the human LXR gene (51,52). This regulation is mediated through an LXRE in the distal portion of the LXR gene promoter that confers responsiveness to both LXR and LXRß. Although this region is conserved in both the mouse and human promoter, autoregulation is only observed in human cells, suggesting that humans may be more responsive to LXR agonists than mice. Interestingly, one study identified LXR autoregulation exclusively in macrophages (52), whereas a second study has found autoregulation in adipocytes and hepatocytes (51). The reason for the discrepancy is not clear and calls for further investigation. Nevertheless, the self-induction of LXR in macrophages in response to lipid loading provides a means for amplifying the effects of oxysterols in reverse cholesterol transport.

	LXR REGULATION BY PPARS

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
In addition to autoregulatory control, recent studies have shown that the expression of LXR is also regulated by members of another family of nuclear receptors, the peroxisome proliferator-activated receptors (PPARs). Two subtypes of the PPARs, PPAR and PPAR, are particularly interesting in that they have been well characterized and are involved in lipid metabolism (53). PPAR is abundantly expressed in liver, kidney, heart, and muscle, and regulates genes involved in fatty acid catabolism and lipoprotein production. PPAR is selectively expressed in adipose tissues and governs adipogenesis. Both PPAR subtypes are found in macrophages that are associated with atherosclerotic plaques.

PPARs promote cholesterol efflux in macrophages through an ABCA1 pathway, possibly by mediating expression of LXR (54,55). A PPAR response element (PPRE) has been identified in both the mouse and human LXR gene (51,55). Although one study claims that both PPAR and PPAR agonists can induce LXR expression in macrophages (54), a second study shows that only PPAR can upregulate expression of LXR through the PPRE (55). It has also been reported that PPAR agonists induce the expression of LXR in rat liver (56); however, this observation could not be corroborated (55). Interestingly, no regulation of LXRß has been observed thus far in any studies, implicating distinct roles of LXR and LXRß in certain regulatory pathways. Nevertheless, the transcriptional regulation of LXR by PPARs suggests an overlap between LXR and PPAR signaling pathways. This regulatory relationship, especially in regard to macrophages, may have important therapeutic implications for the treatment of atherosclerosis.

	OTHER POTENTIAL ROLES OF LXRs

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
Subtractive hybridization between wild-type and Lxr null mice has revealed the existence of several somewhat surprising targets of LXR transactivation. One such targeted gene (denoted as YZ-2 in Table 1) encodes a novel, liver-specific protein that shares identity with uridine phosphorylase (Y. Zhang and D. Mangelsdorf, unpublished observation), which is one of the two enzymes involved in the pyrimidine salvage pathway and catalyzes the reversible phosphorolysis of uridine to produce uracil (57). Interestingly, the expression pattern of this novel gene is strikingly similar to that of another LXR-targeted gene, CYP7A1. The novel analog of uridine phosphorylase is expressed, according to a distinct circadian rhythm that also typifies expression of CYP7A1, primarily in the liver and is induced in response to LXR agonists; its expression is reduced in Lxr null animals. Although direct regulation by LXR has not yet been established, this gene is transcriptionally regulated by the orphan nuclear receptor HNF4 (i.e., hepatocyte nuclear factor 4). The metabolism of uridine nucleotides is involved in a variety of biological functions, including cell growth, and sugar and lipid metabolism (58). The regulation of this gene by LXR raises the possibility that LXRs are involved in pyrimidine-dependent metabolic pathways.

As shown in Figure 1, LXRs are also expressed in many tissues other than liver. One site of LXR production that is particular intriguing is the adrenal gland, where a rich supply of cholesterol serves as the precursor to all steroid hormones. Interestingly, several intermediates in the steroidogenic pathway (e.g., 20(S)-hydroxycholesterol and 22(R)-hydroxycholesterol) are potent LXR activators. The function of LXRs in the adrenal gland is not known, but they may serve some role as sterol sensors in regulating availability of cholesterol for steroid synthesis. In some tissues, LXRß is more abundant than LXR, raising the possibility of disparate, tissue-selective roles for the two LXR types. For example, brain predominantly expresses LXRß and synthesizes the potent LXR activator 24(S)-hydroxycholesterol. Although no phenotypic consequence has been specifically observed with respect to the brain in Lxr knockout animals, the high abundance and requirement of cholesterol in brain may well be supported by mechanisms involving LXRs.

	CONCLUSIONS AND THERAPEUTIC IMPLICATIONS

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
The use of Lxr null mice and LXR-selective agonists has identified crucial genes regulated by LXRs, and establishes the important role of LXRs as sterol sensors that govern the absorption, transport, and catabolism of cholesterol (Figure 3). These studies suggest LXRs as exciting therapeutic targets for novel treatment of hypercholesterolemia and atherosclerosis. However, one potential drawback of attempts to exploit LXR agonism is hypertriglyceridemia caused by upregulation of SREBP-1c. Therefore, one goal of future studies should be focused on separating these two effects, possibly by designing LXR- and LXRß-specific agonists. Several lines of evidence suggest that LXR and LXRß have some redundant, but also many distinct functions. For example, in vivo studies show that upregulation of LPL by synthetic LXR ligands is more sensitive to the presence of LXR than LXRß (37). Newer studies also support the concept that the LXR gene is transcriptionally regulated in several tissues (36,51,52,55,56). In contrast, very little is known about the precise role of LXRß, which is expressed abundantly in a myriad of tissues (Figure 1). Clearly, one area of future study will be in differentiating the roles of LXR and LXRß . The design of LXR- and LXRß-selective agonists and identification of LXR subtype–specific pathways may aid in the development of novel therapeutic approaches to fight cholesterol and lipid disorders.

View larger version (38K): [in this window] [in a new window]   Figure 3. Model describing the LXR regulatory pathways governing lipid metabolism. In liver, intestine, and macrophages, LXRs regulate the expression of genes involved in bile acid synthesis (green box), fatty acid synthesis (red boxes), and cholesterol efflux and transport (blue boxes). LXRs sense intracellular cholesterol levels to help maintain cholesterol homeostasis by increasing bile acid excretion, reducing cholesterol absorption, and increasing cholesterol transport back to the liver for catabolism and storage. (C, cholesterol; CE, cholesterol ester; BA, bile acid; FA, fatty acid; TG, triglyceride; HDL, high density lipoprotein; VLDL, very low density lipoprotein; LDL, low density lipoprotein. See text for details.)

David Mangelsdorf, PhD, is Professor of Pharmacology and Adjunct Professor of Biochemistry at the University of Texas Southwestern Medical Center at Dallas, and an Associate Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Northern Arizona University in Flagstaff before pursuing doctoral work in biochemistry at the University of Arizona in Tucson. Before joining UT Southwestern in 1993, he worked as a postdoc on the retinoid X receptor at the Salk Institute. Dr. Mangelsdorf has received several honors including the ASPET John J. Abel Award, the Endocrine Society Richard A. Weitzman Memorial Award, and the Falk Foundation's Adolf Windaus Prize. Yuan Zhang, PhD, received her undergraduate training at the University of Science and Technology of China in Hefei. In 2001, Dr. Zhang completed her doctoral work in the Mangelsdorf laboratory at UT Southwestern, where she is now continuing her research as a postdoctoral fellow.

	ACKNOWLEDGEMENTS

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 
We thank Dr. Joyce J. Repa for her advice and suggestions during the preparation of this manuscript. We thank the Mango lab for their criticism and support. YZ is a postdoctoral fellow in the Department of Pharmacology at the University of Texas Southwestern Medical Center. DJM is an investigator of the Howard Hughes Medical Institute. This work was also supported by grants from the Robert A. Welch Foundation, the NIH, and the Human Frontier Science Program.

	References

TOP Abstract INTRODUCTION CHOLESTEROL HOMEOSTASIS FATTY ACID SYNTHESIS HUMAN LXR{alpha} AUTOREGULATION LXR{alpha} REGULATION BY PPARS OTHER POTENTIAL ROLES OF... CONCLUSIONS AND THERAPEUTIC... Acknowledgements References

 

1. Mangelsdorf, D.J., Thummel, C., Beato, M. et al. The nuclear receptor superfamily: The second decade. Cell 83, 835–839 (1995).[CrossRef][Medline]
2. Apfel, R., Benbrook, D., Lernhardt, E., Ortiz, M.A., Salbert, G., and Pfahl, M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 14, 7025–7035 (1994).[Abstract/Free Full Text]
3. Willy, P.J., Umesono, K., Ong, E.S., Evans, R.M., Heyman, R.A., and Mangelsdorf, D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033–1045 (1995).[Abstract/Free Full Text]
4. Repa, J.J. and Mangelsdorf, D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459–481 (2000).[CrossRef][Medline]
5. Lu, T.T., Repa, J.J., and Mangelsdorf, D.J. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 276, 37735–37738 (2001).[Free Full Text]
6. Repa, J.J. and Mangelsdorf, D.J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10, 557–563 (1999).[CrossRef][Medline]
7. Janowski, B.A., Willy, P.J., Devi, T.R., Falck, J.R., and Mangelsdorf, D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383, 728–731 (1996).[CrossRef][Medline]
8. Lehmann, J.M., Kliewer, S.A., Moore, L.B. et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137–3140 (1997).[Abstract/Free Full Text]
9. Janowski, B.A., Grogan, M.J., Jones, S.A., Wisely, G.B., Kliewer, S.A., Corey, E.J., and Mangelsdorf, D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 96, 266–271 (1999).[Abstract/Free Full Text]
10. Spencer, T.A., Li, D., Russel, J.S. et al. Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. J. Med. Chem. 44, 886–897 (2001).[CrossRef][Medline]
11. Fu, X., Menke, J.G., Chen, Y., Zhou, G., MacNaul, K.L., Wright, S.D., Sparrow, C.P., and Lund, E.G. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276, 38378–38387 (2001).[Abstract/Free Full Text]
12. Repa, J.J., Turley, S.D., Lobaccaro, J.A. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524–1529 (2000).[Abstract/Free Full Text]
13. Oliver, W.R., Shenk, J.L., Snaith, M.R. et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98, 5306–5311 (2001).[Abstract/Free Full Text]
14. Peet, D.J., Turley, S.D., Ma, W., Janowski, B.A., Lobaccaro, J.M., Hammer, R.E., and Mangelsdorf, D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693–704 (1998).[CrossRef][Medline]
15. Alberti, S., Schuster, G., Parini, P., Feltkamp, D., Diczfalusy, U., Rudling, M., Angelin, B., Bjorkhem, I., Pettersson, S., and Gustafsson, J.A. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 107, 565–573 (2001).[Medline]
16. Russell, D.W. and Setchell, K.D. Bile acid biosynthesis. Biochemistry 31, 4737–4749 (1992).[CrossRef][Medline]
17. Vlahcevic, Z.R., Pandak, W.M., and Stravitz, R.T. Regulation of bile acid biosynthesis. Gastroenterol. Clin. North Am.28, 1–25, (1999).[CrossRef][Medline]
18. Lu, T.T., Makishima, M., Repa, J.J., Schoonjans, K., Kerr, T.A., Auwerx, J., and Mangelsdorf, D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507–515 (2000).[CrossRef][Medline]
19. Goodwin, B., Jones, S.A., Price, R.R. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517–526 (2000).[CrossRef][Medline]
20. Costet, P., Luo, Y., Wang, N., and Tall, A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275, 28240–28245 (2000).[Abstract/Free Full Text]
21. Schwartz, K., Lawn, R.M., and Wade, D.P. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274, 794–802 (2000).[CrossRef][Medline]
22. Singaraja, R.R., Bocher, V., James, E.R. et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J. Biol. Chem. 276, 33969–33979 (2001).[Abstract/Free Full Text]
23. Dean, M., Hamon, Y., and Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 1007–1017 (2001).[Abstract/Free Full Text]
24. Berge, K.E., Tian, H., Graf, G.A. et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290, 1771–1775 (2000).[Abstract/Free Full Text]
25. Brooks-Wilson, A., Marcil, M., Clee, S.M. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22, 336–345 (1999).[CrossRef][Medline]
26. Bodzioch, M., Orso, E., Klucken, J. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22, 347–351 (1999).[CrossRef][Medline]
27. Rust, S., Rosier, M., Funke, H. et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22, 352–355 (1999).[CrossRef][Medline]
28. Venkateswaran, A., Laffitte, B.A., Joseph, S.B., Mak, P.A., Wilpitz, D.C., Edwards, P.A., and Tontonoz, P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 97, 12097–12102 (2000).[Abstract/Free Full Text]
29. Venkateswaran, A., Repa, J.J., Lobaccaro, J.M., Bronson, A., Mangelsdorf, D.J., and Edwards, P.A. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275, 14700–14707 (2000).[Abstract/Free Full Text]
30. Klucken, J., Buchler, C., Orso, E. et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA 97, 817–822 (2000).[Abstract/Free Full Text]
31. Kennedy, M.A., Venkateswaran, A., Tarr, P.T., Xenarios, I., Kudoh, J., Shimizu, N., and Edwards, P.A. Characterization of the human abcg1 gene. Liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276, 39438–39447 (2001).[Abstract/Free Full Text]
32. Dean, M., Rzhetsky, A., and Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156–1166 (2001).[Abstract/Free Full Text]
33. Engel, T., Lorkowski, S., Lueken, A., Rust, S., Schluter, B., Berger, G., Cullen, P., and Assmann, G. The human abcg4 gene is regulated by oxysterols and retinoids in monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 288, 483–488 (2001).[CrossRef][Medline]
34. Laffitte, B.A., Repa, J.J., Joseph, S.B., Wilpitz, D.C., Kast, H.R., Mangelsdorf, D.J., and Tontonoz, P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA 98, 507–512 (2001).[Abstract/Free Full Text]
35. Tall, A. Plasma lipid transfer proteins. Annu. Rev. Biochem. 64, 235–257 (1995).[CrossRef][Medline]
36. Luo, Y. and Tall, A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105, 513–520 (2000).[Medline]
37. Zhang, Y., Repa, J.J., Gauthier, K., and Mangelsdorf, D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J. Biol. Chem. 276, 43018–43024 (2001).[Abstract/Free Full Text]
38. Eckel, R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N. Engl. J. Med. 320, 1060–1068 (1989).[Abstract]
39. Rinninger, F., Kaiser, T., Mann, W.A., Meyer, N., Greten, H., and Beisiegel, U. Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture. J. Lipid Res. 39, 1335–1348 (1998).[Abstract/Free Full Text]
40. Strauss, J.G., Frank, S., Kratky, D., Hammerle, G., Hrzenjak, A., Knipping, G., von Eckardstein, A., Kostner, G.M., and Zechner, R. Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J. Biol. Chem. 276, 36083–36090 (2001).[Abstract/Free Full Text]
41. Claudel, T., Leibowitz, M.D., Fievet, C. et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA 98, 2610–2615 (2001).[Abstract/Free Full Text]
42. Repa, J.J., Liang, G., Ou, J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14, 2819–2830 (2000).[Abstract/Free Full Text]
43. Schultz, J.R., Tu, H., Luk, A. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831–2838 (2000).[Abstract/Free Full Text]
44. Yoshikawa, T., Shimano, H., Amemiya-Kudo, M. et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21, 2991–3000 (2001).[Abstract/Free Full Text]
45. Kim, J.B. and Spiegelman, B.M. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096–1107 (1996).[Abstract/Free Full Text]
46. Horton, J.D. and Shimomura, I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 10, 143–150 (1999).[CrossRef][Medline]
47. Shimano, H., Yahagi, N., Amemiya-Kudo, M. et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274, 35832–35839 (1999).[Abstract/Free Full Text]
48. de The, H., Vivanco-Ruiz, M.M., Tiollais, P., Stunnenberg, H., and Dejean, A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 343, 177–180 (1990).[CrossRef][Medline]
49. Sucov, H.M., Murakami, K.K., and Evans, R.M. Characterization of an autoregulated response element in the mouse retinoic acid receptor type beta gene. Proc. Natl. Acad. Sci. USA 87, 5392–5396 (1990).[Abstract/Free Full Text]
50. Hoffmann, B., Lehmann, J.M., Zhang, X.K., Hermann, T., Husmann, M., Graupner, G., and Pfahl, M. A retinoic acid receptor-specific element controls the retinoic acid receptor-beta promoter. Mol. Endocrinol. 4, 1727–1736 (1990).[Abstract/Free Full Text]
51. Laffitte, B.A., Joseph, S.B., Walczak, R., Pei, L., Wilpitz, D.C., Collins, J.L., and Tontonoz, P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell. Biol. 21, 7558–7568 (2001).[Abstract/Free Full Text]
52. Whitney, K.D., Watson, M.A., Goodwin, B., Galardi, C.M., Maglich, J.M., Wilson, J.G., Willson, T.M., Collins, J.L., and Kliewer, S.A. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 276, 43509–43515 (2001).[Abstract/Free Full Text]
53. Desvergne, B. and Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 20, 649–688 (1999).[Abstract/Free Full Text]
54. Chinetti, G., Lestavel, S., Bocher, V. et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53–58 (2001).[CrossRef][Medline]
55. Chawla, A., Boisvert, W.A., Lee, C.H. et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161–171 (2001).[CrossRef][Medline]
56. Tobin, K.A., Steineger, H.H., Alberti, S., Spydevold, O., Auwerx, J., Gustafsson, J.A., and Nebb, H.I. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol. Endocrinol. 14, 741–752 (2000).[Abstract/Free Full Text]
57. Anderson, C.M. and Parkinson, F.E. Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides. Trends Pharmacol. Sci. 18, 387–392 (1997).[Medline]
58. Connolly, G.P. and Duley, J.A. Uridine and its nucleotides: Biological actions, therapeutic potentials. Trends Pharmacol. Sci. 20, 218–225 (1999).[CrossRef][Medline]
59. Repa, J.J., Berge, K.E., Pomajzl, C., Richardson, J.A., Hobbs, H., and Mangelsdorf, D.J. Regulation of ATP-binding cassette sterol transporters, ABCG5 and ABCG8, by the oxysterol receoptors, LXR and ß. J. Biol. Chem. (in press).

This article has been cited by other articles:

				L. Cruz-Garcia, A. Saera-Vila, I. Navarro, J. Calduch-Giner, and J. Perez-Sanchez Targets for TNF{alpha}-induced lipolysis in gilthead sea bream (Sparus aurata L.) adipocytes isolated from lean and fat juvenile fish J. Exp. Biol., July 15, 2009; 212(14): 2254 - 2260. [Abstract] [Full Text] [PDF]

				C. Gabbi, M. Warner, and J.-A. Gustafsson Minireview: Liver X Receptor {beta}: Emerging Roles in Physiology and Diseases Mol. Endocrinol., February 1, 2009; 23(2): 129 - 136. [Abstract] [Full Text] [PDF]

				M. Noshiro, E. Usui, T. Kawamoto, F. Sato, A. Nakashima, T. Ueshima, K. Honda, K. Fujimoto, S. Honma, K.-i. Honma, et al. Liver X receptors (LXR{alpha} and LXR{beta}) are potent regulators for hepatic Dec1 expression Genes Cells, January 1, 2009; 14(1): 29 - 40. [Abstract] [Full Text] [PDF]

				C. Gabbi, H.-J. Kim, K. Hultenby, D. Bouton, G. Toresson, M. Warner, and J.-A. Gustafsson Pancreatic exocrine insufficiency in LXR{beta}-/- mice is associated with a reduction in aquaporin-1 expression PNAS, September 30, 2008; 105(39): 15052 - 15057. [Abstract] [Full Text] [PDF]

				K. Smoak, J. Madenspacher, S. Jeyaseelan, B. Williams, D. Dixon, K. R. Poch, J. A. Nick, G. S. Worthen, and M. B. Fessler Effects of Liver X Receptor Agonist Treatment on Pulmonary Inflammation and Host Defense J. Immunol., March 1, 2008; 180(5): 3305 - 3312. [Abstract] [Full Text] [PDF]

				H. Zitzer, W. Wente, M. B. Brenner, S. Sewing, K. Buschard, J. Gromada, and A. M. Efanov Sterol Regulatory Element-Binding Protein 1 Mediates Liver X Receptor-{beta}-Induced Increases in Insulin Secretion and Insulin Messenger Ribonucleic Acid Levels Endocrinology, August 1, 2006; 147(8): 3898 - 3905. [Abstract] [Full Text] [PDF]

				F. Grun and B. Blumberg Environmental Obesogens: Organotins and Endocrine Disruption via Nuclear Receptor Signaling Endocrinology, June 1, 2006; 147(6): s50 - s55. [Abstract] [Full Text] [PDF]

				I. Weinhofer, M. Kunze, H. Rampler, A. L. Bookout, S. Forss-Petter, and J. Berger Liver X Receptor {alpha} Interferes with SREBP1c-mediated Abcd2 Expression: NOVEL CROSS-TALK IN GENE REGULATION J. Biol. Chem., December 16, 2005; 280(50): 41243 - 41251. [Abstract] [Full Text] [PDF]

				A. R. Tovar, I. Torre-Villalvazo, M. Ochoa, A. L. Elias, V. Ortiz, C. A. Aguilar-Salinas, and N. Torres Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats J. Lipid Res., September 1, 2005; 46(9): 1823 - 1832. [Abstract] [Full Text] [PDF]

				M. K. Wu and D. E. Cohen Altered hepatic cholesterol metabolism compensates for disruption of phosphatidylcholine transfer protein in mice Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G456 - G461. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. J. Repa, Y. Inoue, G. P. Hayhurst, F. J. Gonzalez, and D. J. Mangelsdorf Identification of a Liver-Specific Uridine Phosphorylase that Is Regulated by Multiple Lipid-Sensing Nuclear Receptors Mol. Endocrinol., April 1, 2004; 18(4): 851 - 862. [Abstract] [Full Text] [PDF]

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y. Articles by Mangelsdorf, D. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y. Articles by Mangelsdorf, D. J.